Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbralisib + Ublituximab (U2) in Progressive CLL
NCT04149821Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of umbralisib and ublituximab in chronic lymphocytic leukemia (CLL) (2 cohorts), sponsored by Weill Cornell Medicine. Primary endpoint: Overall Response Rate at 11 months. Started Feb 2021; status: terminated.
02
Drugs
umbralisibublituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04149821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04149821.